Sentinel Trial Detects Lung Rejection Early
Analysis based on 8 articles · First reported Apr 07, 2026 · Last updated Apr 08, 2026
The Sentinel trial, if successful, could revolutionize organ transplant procedures by enabling earlier detection of rejection, potentially leading to better patient outcomes and reduced healthcare costs. This innovation could positively impact the medical device and pharmaceutical sectors involved in transplant care.
The Sentinel trial is a medical study investigating the use of skin patches from organ donors to detect organ rejection earlier in lung transplant patients. Darren White, a 53-year-old former bus driver, was one of the first patients to receive a skin patch during his lung transplant in late 2024. Three months post-surgery, a purple rash on his skin patch indicated mild rejection, leading to swift steroid treatment. This early detection, facilitated by the skin patch acting as a 'window' to the transplant, prevented further damage to his new lung. The trial, led by Henk Giele and supported by United Kingdom===NHS Blood and Transplant and the University of Oxford, aims to recruit 152 patients across five UK hospitals until 2027. Experts believe this method could significantly improve patient lives by allowing for earlier intervention against organ rejection.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard